Alison L Allan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2559318/publications.pdf

Version: 2024-02-01

42 papers	3,038 citations	257450 24 h-index	276875 41 g-index
44 all docs	44 docs citations	44 times ranked	5135 citing authors

#	Article	IF	Citations
1	Exploitation of treatment induced tumor lysis to enhance the sensitivity of ctDNA analysis: A first-in-human pilot study. Lung Cancer, 2022, 165, 145-151.	2.0	6
2	A survivin-driven, tumor-activatable minicircle system for prostate cancer theranostics. Molecular Therapy - Oncolytics, 2021, 20, 209-219.	4.4	9
3	EMT-independent detection of circulating tumor cells in human blood samples and pre-clinical mouse models of metastasis. Clinical and Experimental Metastasis, 2021, 38, 97-108.	3.3	16
4	Lung-Derived Selectins Enhance Metastatic Behavior of Triple Negative Breast Cancer Cells. Biomedicines, 2021, 9, 1580.	3.2	5
5	Reduced Zeb1 Expression in Prostate Cancer Cells Leads to an Aggressive Partial-EMT Phenotype Associated with Altered Global Methylation Patterns. International Journal of Molecular Sciences, 2021, 22, 12840.	4.1	9
6	Stereotactic ablative radiotherapy for the comprehensive treatment of 1â€“3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial. BMC Cancer, 2020, 20, 380.	2.6	75
7	Exploitation of treatment induced tumor lysis to enhance sensitivity of ctDNA analysis: A first-in-human pilot study.. Journal of Clinical Oncology, 2020, 38, 3530-3530.	1.6	2
8	Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples. Journal of Visualized Experiments, 2020, , .	0.3	0
9	Stereotactic ablative radiotherapy for the comprehensive treatment of 4â€“10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer, 2019, 19, 816.	2.6	165
10	Role of the Microenvironment in Regulating Normal and Cancer Stem Cell Activity: Implications for Breast Cancer Progression and Therapy Response. Cancers, 2019, 11, 1240.	3.7	23
11	On-Chip Preparation of Amphiphilic Nanomicellesâ€“inâ€“Sodium Alginate Spheroids as a Novel Platform Against Triple-Negative Human Breast Cancer Cells: Fabrication, Study of Microfluidics Flow Hydrodynamics and Proof of Concept for Anticancer and Drug Delivery Applications. Journal of Pharmaceutical Sciences, 2019, 108, 3528-3539.	3.3	11
12	Magnetically Guided Self-Assembled Protein Micelles for Enhanced Delivery of Dasatinib to Human Triple-Negative Breast Cancer Cells. Journal of Pharmaceutical Sciences, 2019, 108, 1713-1725.	3.3	47
13	Molecular Mechanisms of Breast Cancer Metastasis to the Lung: Clinical and Experimental Perspectives. International Journal of Molecular Sciences, 2019, 20, 2272.	4.1	143
14	Examination of the additive value of CTC biomarkers of heterogeneity (Het) and chromosomal instability to nuclear-localized (nl) AR-V7+ CTCs in prediction of poor outcomes to androgen receptor signaling inhibitor (ARSi) in metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2019, 37, 5075-5075.	1.6	2
15	Self-assembled amphiphilic zein-lactoferrin micelles for tumor targeted co-delivery of rapamycin and wogonin to breast cancer. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 128, 156-169.	4.3	124
16	Circulating Tumor Cells and Implications of the Epithelial-to-Mesenchymal Transition. Advances in Clinical Chemistry, 2018, 83, 121-181.	3.7	35
17	Circulating Tumor Cell Analysis in Preclinical Mouse Models of Metastasis. Diagnostics, 2018, 8, 30.	2.6	22
18	Validation of nuclear-localized AR-V7 on circulating tumor cells (CTC) as a treatment-selection biomarker for managing metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2018, 36, 273-273.	1.6	5

#	Article	IF	Citations
19	A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209. Oncotarget, 2018, 9, 8155-8164.	1.8	18
20	Differential Functional Roles of ALDH1A1 and ALDH1A3 in Mediating Metastatic Behavior and Therapy Resistance of Human Breast Cancer Cells. International Journal of Molecular Sciences, 2017, 18, 2039.	4.1	70
21	Soluble bone-derived osteopontin promotes migration and stem-like behavior of breast cancer cells. PLoS ONE, 2017, 12, e0177640.	2.5	33
22	Generation of Organ-conditioned Media and Applications for Studying Organ-specific Influences on Breast Cancer Metastatic Behavior. Journal of Visualized Experiments, 2016, , .	0.3	2
23	Aldehyde dehydrogenase as a marker and functional mediator of metastasis in solid tumors. Clinical and Experimental Metastasis, 2016, 33, 97-113.	3.3	108
24	Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer. Oncotarget, 2016, 7, 76125-76139.	1.8	29
25	Recent Advances in the Molecular Characterization of Circulating Tumor Cells. Cancers, 2014, 6, 595-624.	3.7	56
26	Lung-Derived Factors Mediate Breast Cancer Cell Migration through CD44 Receptor-Ligand Interactions in a Novel Ex Vivo System for Analysis of Organ-Specific Soluble Proteins. Neoplasia, 2014, 16, 180-W27.	5.3	31
27	Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications. Journal of Visualized Experiments, 2014, , e51248.	0.3	9
28	Response to Rossi et al.. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2013, 83A, 599-601.	1.5	0
29	NCIC CTG, IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2013, 31, 5042-5042.	1.6	3
30	Userâ€defined protein marker assay development for characterization of circulating tumor cells using the CellSearchÂ® system. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2012, 81A, 983-995.	1.5	26
31	Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44+ human breast cancer cells. Breast Cancer Research and Treatment, 2012, 133, 75-87.	2.5	265
32	The Role of Human Aldehyde Dehydrogenase in Normal and Cancer Stem Cells. Stem Cell Reviews and Reports, 2011, 7, 292-306.	5.6	442
33	Circulating Tumor Cell Analysis: Technical and Statistical Considerations for Application to the Clinic. Journal of Oncology, 2010, 2010, 1-10.	1.3	170
34	Recombinant Human Erythropoietin (rHuEPO) In Combination with Chemotherapy Increases Breast Cancer Metastasis In Pre-Clinical Mouse Models. Blood, 2010, 116, 3345-3345.	1.4	0
35	High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. Journal of Cellular and Molecular Medicine, 2009, 13, 2236-2252.	3.6	451
36	Characterization of tumor cell dissemination patterns in preclinical models of cancer metastasis using flow cytometry and laser scanning cytometry. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2009, 75A, 344-355.	1.5	46

#	Article	IF	Citations
37	Flow cytometric assessment of monocyte activation markers and circulating endothelial cells in patients with localized or metastatic breast cancer. Cytometry Part B - Clinical Cytometry, 2009, 76B, 107-117.	1.5	22
38	The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms. Breast Cancer Research and Treatment, 2008, 112, 243-254.	2.5	51
39	Tumor Dormancy and Cancer Stem Cells: Implications for the Biology and Treatment of Breast Cancer Metastasis. Breast Disease, 2007, 26, 87-98.	0.8	139
40	Osteopontin overexpression in breast cancer: Knowledge gained and possible implications for clinical management. Journal of Cellular Biochemistry, 2007, 102, 859-868.	2.6	120
41	Role of the Integrin-Binding Protein Osteopontin in Lymphatic Metastasis of Breast Cancer. American Journal of Pathology, 2006, 169, 233-246.	3.8	94
42	Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Molecular Cancer Research, 2003, 1, 810-9.	3.4	76